Sunday, September 28, 2014
Rosuvastatin promotes bone growth in mice with achondroplasia symptoms
Friday, November 1, 2013
New Cholesterol-Lowering Drug, ALN-PCS Shows Early Promise
"Cardiovascular disease remains the leading cause of death of men and women globally and reduction of LDL cholesterol with statin medications has been demonstrated to substantially reduce the risk of first or recurrent cardiovascular events," said Dr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles.
Sunday, January 6, 2013
Common cholesterol-lowering drug may help protect against cerebral malaria
"The molecular mechanisms that give rise to cerebral malaria and subsequent cognitive dysfunction are not yet known," says Zimmerman. "However, the fact that statin treatment decreases both injurious blood vessel inflammation and cognitive dysfunction suggests that a combination of vascular and inflammatory triggers leads to cerebral pathology and intellectual deficits."Ref : http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1003099
Common cholesterol-lowering drug may help protect against cerebral malaria
Friday, June 8, 2012
Experimental cholesterol drug, REGN727 (PCSK9 inhibitor) results called ‘game changing
“Wars for PCSK9 are far bigger than the statin wars,” said Dr. Evan A Stein, lead author of the study and researcher at the Metabolic and Atherosclerosis Research Center in Cincinnati, Ohio. “This is a hot research area and everybody is so close together.”
Monday, September 6, 2010
Saturday, July 24, 2010
No Firm Conclusions About HDL Cholesterol Can Be Drawn from JUPITER Sub-Analysis
The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet , could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol. Caution, the ESC experts advise, should be displayed in the interpretation of the results.....
In the Lancet study, Paul Ridker and colleagues, from Brigham and Women's Hospital (Boston, MA, USA), undertook a retrospective post-hoc analysis of the JUPITER trial. The results show that if a normal, healthy individual has level of low density lipoprotein (LDL), known as "bad cholesterol", substantially lowered with a potent statin, then the level of HDL "good cholesterol" in that person no longer bears any relation to the remaining cardiovascular risk. More.....
Ref : http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960713-1/fulltext
Wednesday, June 9, 2010
Lovastatin: A New Weapon Against Plague?
Thursday, April 15, 2010
Flaxseed lowers high cholesterol in men.....
Monday, March 15, 2010
Eprotirome a promising addition to statin therapy ?
Interestingly, the researchers caution that the results don't suggest that eprotirome will or should replace statins, which are the current gold standard for treating high LDL cholesterol.